March 13, 2017
FORMA THERAPEUTICS announces achievement of first clinical development milestone in partnership with boehringer ingelheim
February 21, 2017
FORMA THERAPEUTICS AWARDED GRANT FROM MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
FORMA Therapeutics receives grant from MJFF and expands translational research into neurodegenerative diseases through alliance with University of Liverpool and Medical Research Council.
October 11, 2016
FORMA THERAPEUTICS APPOINTS JIM WINKLER, Ph.D., VICE PRESIDENT, DISCOVERY AND TRANSLATIONAL BIOLOGY
FORMA Therapeutics, a clinical-stage and fully integrated research and development company, today announced the appointment of Jim Winkler, Ph.D., as Vice President, Discovery and Translational Biology.
August 31, 2016
FORMA THERAPEUTICS ACHIEVES CLINICAL CANDIDATE LICENSING MILESTONE FOR NASH COMPOUND IN STRATEGIC ALLIANCE WITH CELGENE CORPORATION
FORMA Therapeutics delivers second Phase I-ready compound under Celgene alliance.
August 29, 2016
FORMA THERAPEUTICS APPOINTS KAROLINE SHAIR, Ph.D., J.D., VICE PRESIDENT, LEGAL AND CHIEF INTELLECTUAL PROPERTY COUNSEL
FORMA Therapeutics, a clinical-stage and fully integrated research and development company, today announced the appointment of Karoline Shair, Ph.D., J.D., as Vice President, Legal and Chief Intellectual Property Counsel.
January 12, 2016
FORMA THERAPEUTICS ENROLLS FIRST PATIENT IN PHASE 1 STUDY OF FT-1101 IN ADVANCED HEMATOLOGICAL MALIGNANCIES
FORMA Therapeutics today announced the initiation of a Phase 1 study of FT-1101, with the first dose administration in patients with relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome.
January 12, 2016
FORMA THERAPEUTICS ACHIEVES AN ADDITIONAL MAJOR OBJECTIVE IN COLLABORATION WITH CELGENE CORPORATION TO ADVANCE INNOVATIVE PROTEIN HOMEOSTASIS DRUGS
FORMA Therapeutics announced today that it has successfully met a third objective under its strategic collaboration agreement with Celgene Corporation, triggering an undisclosed payment from Celgene.